A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

BACKGROUND: Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Colin J., Towfic, Fadi, Shankar, Jyoti, Laifenfeld, Daphna, Thoma, Mathis, Davis, Matthew, Weiner, Brian, Kusko, Rebecca, Zeskind, Ben, Knappertz, Volker, Grossman, Iris, Hayden, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450152/
https://www.ncbi.nlm.nih.gov/pubmed/28569182
http://dx.doi.org/10.1186/s13073-017-0436-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450152/
https://www.ncbi.nlm.nih.gov/pubmed/28569182
http://dx.doi.org/10.1186/s13073-017-0436-y

Ejemplares similares